Studying furosemide solubilization using an in vitro model simulating gastrointestinal digestion and drug solubilization in neonates and young infants

The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0–2months). The util...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of pharmaceutical sciences Vol. 109; pp. 191 - 199
Main Authors Klitgaard, Mette, Sassene, Philip Jonas, Selen, Arzu, Müllertz, Anette, Berthelsen, Ragna
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.11.2017
Subjects
Online AccessGet full text
ISSN0928-0987
1879-0720
1879-0720
DOI10.1016/j.ejps.2017.08.003

Cover

Abstract The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0–2months). The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo. The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder. [Display omitted]
AbstractList The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0–2months). The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo. The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder. [Display omitted]
The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0-2months).OBJECTIVEThe aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0-2months).The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo.METHODSThe utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo.The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder.KEY FINDINGS AND CONCLUSIONSThe present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder.
The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0-2months). The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo. The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder.
Author Selen, Arzu
Müllertz, Anette
Berthelsen, Ragna
Klitgaard, Mette
Sassene, Philip Jonas
Author_xml – sequence: 1
  givenname: Mette
  surname: Klitgaard
  fullname: Klitgaard, Mette
  email: sfv995@sund.ku.dk
  organization: Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
– sequence: 2
  givenname: Philip Jonas
  surname: Sassene
  fullname: Sassene, Philip Jonas
  email: dlt527@alumni.ku.dk
  organization: Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
– sequence: 3
  givenname: Arzu
  surname: Selen
  fullname: Selen, Arzu
  email: arzu.Selen@fda.hhs.gov
  organization: Office of Testing and Research, US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, United States
– sequence: 4
  givenname: Anette
  surname: Müllertz
  fullname: Müllertz, Anette
  email: anette.mullertz@sund.ku.dk
  organization: Bioneer:FARMA, Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
– sequence: 5
  givenname: Ragna
  orcidid: 0000-0002-5992-9688
  surname: Berthelsen
  fullname: Berthelsen, Ragna
  email: ragna.berthelsen@sund.ku.dk
  organization: Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28803922$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtv1DAUhS1URKeFP8ACZckm4dp52JHYoIqXVIkFsLac-GZ0R4k92HGl4Yfwe3E67aaLrvy45zuyz7liF847ZOwth4oD7z4cKjwcYyWAywpUBVC_YDuuZF-CFHDBdtALVUKv5CW7ivEAAJ2S8IpdCqWg7oXYsX8_12RP5PbFlIKPuJDFIvo5DTTTX7OSd0WK29y4glxxR2vwxeItzkWkJc1Zkod7E_M9uRVjPpu5sLTftpk2zhY2pP1T12zm0DuTkXvNyadsRG4ybo2v2cvJzBHfPKzX7PeXz79uvpW3P75-v_l0W451260lHwaU2GKrBo7WSNENk-jGusF-mKTktm94Y1SeGOgaVA0Mth0Ehw5bsD3W1-z92fcY_J-UX6wXiiPOs8lvS1HznKBUAmqVpe8epGlY0OpjoMWEk37MMgvUWTDmIGPASY-03v91DYZmzUFvtemD3mrTW20alM61ZVQ8QR_dn4U-niHMAd0RBh1HQjeipYDjqq2n5_D_R0O2bw
CitedBy_id crossref_primary_10_1039_D0FO01981J
crossref_primary_10_1016_j_addr_2019_03_005
crossref_primary_10_1016_j_tifs_2023_104306
crossref_primary_10_3390_pharmaceutics12040365
crossref_primary_10_1111_jphp_12955
crossref_primary_10_1016_j_ejps_2021_105828
crossref_primary_10_3389_fimmu_2018_01098
crossref_primary_10_1016_j_foodchem_2024_142151
crossref_primary_10_1146_annurev_food_060721_025159
crossref_primary_10_1016_j_ijpharm_2024_124286
crossref_primary_10_1016_j_cis_2023_103028
crossref_primary_10_1016_j_apsb_2021_03_025
crossref_primary_10_1039_D0FO02976A
crossref_primary_10_1016_j_addr_2019_06_010
Cites_doi 10.1208/s12248-014-9672-x
10.1517/17425255.2012.698261
10.1136/adc.37.194.387
10.1542/peds.72.5.677
10.1016/j.ejps.2015.05.023
10.1016/j.biochi.2015.11.016
10.3390/pharmaceutics2040364
10.1080/10408398.2011.640757
10.1039/C6FO00158K
10.1038/nrd2197
10.1002/jps.23205
10.1002/jps.22030
10.1007/s11095-009-9906-2
10.1016/0009-8981(59)90030-0
10.1007/BF00615967
10.1016/j.ijpharm.2013.07.053
10.1016/0016-5085(93)90908-U
10.1016/j.jpba.2013.05.011
10.1023/A:1016212804288
10.1542/peds.62.5.811
10.1111/jphp.12365
10.1023/A:1011984216775
10.1159/000244419
10.1203/00006450-199609000-00011
ContentType Journal Article
Copyright 2017 Elsevier B.V.
Copyright © 2017 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2017 Elsevier B.V.
– notice: Copyright © 2017 Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ejps.2017.08.003
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1879-0720
EndPage 199
ExternalDocumentID 28803922
10_1016_j_ejps_2017_08_003
S0928098717304475
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
53G
5GY
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AATCM
AAXUO
ABFRF
ABJNI
ABLJU
ABMAC
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
GROUPED_DOAJ
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SPCBC
SSP
SSZ
T5K
TEORI
~G-
29G
5VS
AAQFI
AAQXK
AATTM
AAXKI
AAYWO
AAYXX
ABFNM
ABWVN
ABXDB
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
ADPDF
ADVLN
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
ASPBG
AVWKF
AZFZN
BNPGV
CITATION
FEDTE
FGOYB
G-2
HMT
HVGLF
HZ~
OK1
R2-
SEW
SPT
SSH
WUQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
EFKBS
ID FETCH-LOGICAL-c356t-1bbe7e5e58b1eda726bf26c34e9bf771d9414a8da7a064e840bd5b2106e50d9e3
IEDL.DBID AIKHN
ISSN 0928-0987
1879-0720
IngestDate Fri Sep 05 10:43:55 EDT 2025
Thu Apr 03 06:55:59 EDT 2025
Tue Jul 01 02:04:16 EDT 2025
Thu Apr 24 22:58:35 EDT 2025
Fri Feb 23 02:19:42 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords In vitro models
Digestion
Pediatric
Drug solubilization
Furosemide
Neonates and young infants
Language English
License Copyright © 2017 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c356t-1bbe7e5e58b1eda726bf26c34e9bf771d9414a8da7a064e840bd5b2106e50d9e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5992-9688
PMID 28803922
PQID 1928782038
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1928782038
pubmed_primary_28803922
crossref_citationtrail_10_1016_j_ejps_2017_08_003
crossref_primary_10_1016_j_ejps_2017_08_003
elsevier_sciencedirect_doi_10_1016_j_ejps_2017_08_003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-11-15
PublicationDateYYYYMMDD 2017-11-15
PublicationDate_xml – month: 11
  year: 2017
  text: 2017-11-15
  day: 15
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle European journal of pharmaceutical sciences
PublicationTitleAlternate Eur J Pharm Sci
PublicationYear 2017
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Kassab (bb0130) 2015; 11
U.S.Department of Health and Human Services Food and Drug Administration (bb0180) 2005
Havenaar (bb0110) 2013; 457
Zisowsky (bb0195) 2010; 2
Amidon (bb0020) 1995; 12
Administration USDoHaHSFaD (bb0005) 2001
Takacs-Novak (bb0170) 2013; 83
Administration USDoHaHSFaD (bb0015) March 2016
Mason (bb0135) 1962; 37
Armand (bb0025) 1996; 40
Otsuka (bb0150) 2015; 67
Sassene (bb0160) 2014; 16
Mooij (bb0140) 2012; 8
Nestlé (bb0145)
Carriere (bb0055) 2016; 125
Beermann, Midskov (bb0030) 1986; 29
European Medicines Agency (bb0080) 2006
European Medicines Agency (bb0085) 2007
U.S.Department of Health and Human Services Food and Drug Administration (bb0185) 2015
Berthelsen (bb0035) 2016
Engle (bb0075) 1978; 62
Administration USDoHaHSFaD (bb0010) 2014
Dressman (bb0065) 1998; 15
Boehm (bb0040) 1997; 71
Frusol (bb0095) 2015
Williams (bb0190) 2012; 101
Encrantz, Sjövall (bb0070) 1959; 4
Hens (bb0115) 2015; 77
Sassene (bb0165) 2016; 7
Kamstrup (bb0125) 2016
Carriere (bb0060) 1993; 105
European Medicines Agency (bb0090) 2016
Granero (bb0105) 2010; 99
Fernandez (bb2015) 2009; 26
Furix (bb0100) 2013
Jarvenpaa (bb0120) 1983; 72
Buck (bb0050) 2009; 15
Porter (bb0155) 2007; 6
The European Commision. Better Medicines for Children From Concept to Reality (bb0175) 2013; 443
Bourlieu (bb0045) 2014; 54
Mooij (10.1016/j.ejps.2017.08.003_bb0140) 2012; 8
Nestlé (10.1016/j.ejps.2017.08.003_bb0145)
Carriere (10.1016/j.ejps.2017.08.003_bb0060) 1993; 105
Havenaar (10.1016/j.ejps.2017.08.003_bb0110) 2013; 457
Jarvenpaa (10.1016/j.ejps.2017.08.003_bb0120) 1983; 72
The European Commision. Better Medicines for Children From Concept to Reality (10.1016/j.ejps.2017.08.003_bb0175) 2013; 443
European Medicines Agency (10.1016/j.ejps.2017.08.003_bb0085) 2007
Sassene (10.1016/j.ejps.2017.08.003_bb0165) 2016; 7
Furix (10.1016/j.ejps.2017.08.003_bb0100)
U.S.Department of Health and Human Services Food and Drug Administration (10.1016/j.ejps.2017.08.003_bb0180) 2005
Sassene (10.1016/j.ejps.2017.08.003_bb0160) 2014; 16
Granero (10.1016/j.ejps.2017.08.003_bb0105) 2010; 99
U.S.Department of Health and Human Services Food and Drug Administration (10.1016/j.ejps.2017.08.003_bb0185)
Administration USDoHaHSFaD (10.1016/j.ejps.2017.08.003_bb0010) 2014
Carriere (10.1016/j.ejps.2017.08.003_bb0055) 2016; 125
Williams (10.1016/j.ejps.2017.08.003_bb0190) 2012; 101
Berthelsen (10.1016/j.ejps.2017.08.003_bb0035) 2016
European Medicines Agency (10.1016/j.ejps.2017.08.003_bb0090)
Administration USDoHaHSFaD (10.1016/j.ejps.2017.08.003_bb0015) 2016
Armand (10.1016/j.ejps.2017.08.003_bb0025) 1996; 40
Frusol (10.1016/j.ejps.2017.08.003_bb0095)
Kamstrup (10.1016/j.ejps.2017.08.003_bb0125) 2016
Amidon (10.1016/j.ejps.2017.08.003_bb0020) 1995; 12
Beermann (10.1016/j.ejps.2017.08.003_bb0030) 1986; 29
Dressman (10.1016/j.ejps.2017.08.003_bb0065) 1998; 15
Mason (10.1016/j.ejps.2017.08.003_bb0135) 1962; 37
Otsuka (10.1016/j.ejps.2017.08.003_bb0150) 2015; 67
Engle (10.1016/j.ejps.2017.08.003_bb0075) 1978; 62
Buck (10.1016/j.ejps.2017.08.003_bb0050) 2009; 15
Administration USDoHaHSFaD (10.1016/j.ejps.2017.08.003_bb0005) 2001
European Medicines Agency (10.1016/j.ejps.2017.08.003_bb0080) 2006
Kassab (10.1016/j.ejps.2017.08.003_bb0130) 2015; 11
Porter (10.1016/j.ejps.2017.08.003_bb0155) 2007; 6
Takacs-Novak (10.1016/j.ejps.2017.08.003_bb0170) 2013; 83
Zisowsky (10.1016/j.ejps.2017.08.003_bb0195) 2010; 2
Bourlieu (10.1016/j.ejps.2017.08.003_bb0045) 2014; 54
Boehm (10.1016/j.ejps.2017.08.003_bb0040) 1997; 71
Encrantz (10.1016/j.ejps.2017.08.003_bb0070) 1959; 4
Hens (10.1016/j.ejps.2017.08.003_bb0115) 2015; 77
Fernandez (10.1016/j.ejps.2017.08.003_bb2015) 2009; 26
References_xml – volume: 83
  start-page: 279
  year: 2013
  end-page: 285
  ident: bb0170
  article-title: Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid
  publication-title: J. Pharm. Biomed. Anal.
– start-page: 2016
  year: March 2016
  ident: bb0015
  article-title: Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Study Plans. Guidance for Industry. Draft Guidance. Draft Guidance
– volume: 15
  start-page: 11
  year: 1998
  end-page: 22
  ident: bb0065
  article-title: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms
  publication-title: Pharm. Res.
– volume: 457
  start-page: 327
  year: 2013
  end-page: 332
  ident: bb0110
  article-title: gastrointestinal model (TIM) with predictive power, even for infants and children?
  publication-title: Int. J. Pharm.
– volume: 67
  start-page: 651
  year: 2015
  end-page: 665
  ident: bb0150
  article-title: Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach
  publication-title: J. Pharm. Pharmacol.
– volume: 2
  start-page: 364
  year: 2010
  end-page: 388
  ident: bb0195
  article-title: Drug development for pediatric populations: regulatory aspects
  publication-title: Pharmaceutics.
– volume: 12
  start-page: 413
  year: 1995
  end-page: 420
  ident: bb0020
  article-title: A theoretical basis for a biopharmaceutic drug classification: the correlation of
  publication-title: Pharm. Res.
– volume: 72
  start-page: 677
  year: 1983
  end-page: 683
  ident: bb0120
  article-title: Feeding the low-birth-weight infant. III. Diet influences bile acid metabolism
  publication-title: Pediatrics
– volume: 101
  start-page: 3360
  year: 2012
  end-page: 3380
  ident: bb0190
  article-title: Toward the establishment of standardized
  publication-title: J. Pharm. Sci.
– volume: 443
  year: 2013
  ident: bb0175
  article-title: Progress Report on the Paediatric Regulation (EC) N1901/2006. Com (2013)
– year: 2015
  ident: bb0185
  article-title: Pediatric product development
– volume: 29
  start-page: 725
  year: 1986
  end-page: 727
  ident: bb0030
  article-title: Reduced bioavailability and effect of furosemide given with food
  publication-title: Eur. J. Clin. Pharmacol.
– volume: 4
  start-page: 793
  year: 1959
  end-page: 799
  ident: bb0070
  article-title: On the bile acids in duodenal contents of infants and children bile acids and steroids 72
  publication-title: Clin. Chim. Acta
– year: 2006
  ident: bb0080
  article-title: EC Regulation No 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 1768/92, directive 2001/20/EC, directive 2001/83/EC and regulation (EC) No 726/2004
  publication-title: Off. J. Eur. Union
– volume: 11
  year: 2015
  ident: bb0130
  article-title: Diuretics for transient tachypnoea of the newborn
  publication-title: Cochrane Database Syst. Rev.
– volume: 71
  start-page: 207
  year: 1997
  end-page: 214
  ident: bb0040
  article-title: Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age
  publication-title: Biol. Neonate
– start-page: 773
  year: 2016
  end-page: 790
  ident: bb0035
  article-title: et al.
  publication-title: Evaluating Oral Drug Delivery Systems: Digestion models Analytical Techniques in the Pharmaceutical Sciences
– year: 2014
  ident: bb0010
  article-title: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products. Guidance for Industry. Draft guidance
– volume: 105
  start-page: 876
  year: 1993
  end-page: 888
  ident: bb0060
  article-title: Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans
  publication-title: Gastroenterology
– volume: 99
  start-page: 2544
  year: 2010
  end-page: 2556
  ident: bb0105
  article-title: Biowaiver monographs for immediate release solid oral dosage forms: furosemide
  publication-title: J. Pharm. Sci.
– volume: 7
  start-page: 3989
  year: 2016
  end-page: 3998
  ident: bb0165
  article-title: Comparison of lipases for
  publication-title: Food Funct.
– year: 2007
  ident: bb0085
  article-title: The European Paediatric Initiative: History of the Paediatric Regulation. Doc Ref: EMEA/17967/04 Rev 1
– year: 2016
  ident: bb0090
  article-title: Paediatric regulations
– volume: 16
  start-page: 1344
  year: 2014
  end-page: 1357
  ident: bb0160
  article-title: Toward the establishment of standardized
  publication-title: AAPS J.
– volume: 6
  start-page: 231
  year: 2007
  end-page: 248
  ident: bb0155
  article-title: Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
  publication-title: Nat. Rev. Drug Discov.
– volume: 62
  start-page: 811
  year: 1978
  end-page: 818
  ident: bb0075
  article-title: The use of furosemide in the treatment of edema in infants and children
  publication-title: Pediatrics
– volume: 77
  start-page: 40
  year: 2015
  end-page: 47
  ident: bb0115
  article-title: Gastrointestinal behavior of nano- and microsized fenofibrate:
  publication-title: Eur. J. Pharm. Sci.
– volume: 40
  start-page: 429
  year: 1996
  end-page: 437
  ident: bb0025
  article-title: Effect of human milk or formula on gastric function and fat digestion in the premature infant
  publication-title: Pediatr. Res.
– volume: 8
  start-page: 1293
  year: 2012
  end-page: 1303
  ident: bb0140
  article-title: Ontogeny of oral drug absorption processes in children
  publication-title: Expert Opin. Drug Metab. Toxicol.
– year: 2005
  ident: bb0180
  article-title: Guidance for Industry. How to Comply With the Pediatric Research Equity Act. Draft Guidance
– year: 2013
  ident: bb0100
  article-title: 20
– volume: 37
  start-page: 387
  year: 1962
  end-page: 391
  ident: bb0135
  article-title: Some aspects of gastric function in the newborn
  publication-title: Arch. Dis. Child.
– volume: 26
  start-page: 1901
  year: 2009
  end-page: 1910
  ident: bb2015
  article-title: In vitro gastrointestinal lipolysis of four formulations of piroxicam ans cannarizine with the self emulsifying excipients Labrosol and Gelucire 44/14
  publication-title: Pharm. Res.
– volume: 15
  year: 2009
  ident: bb0050
  article-title: Furosemide: a review of its use in infants and children
  publication-title: Pediatr. Pharmacol.
– year: 2015
  ident: bb0095
  article-title: 20mg/5ml Oral Solution. RosemontPharmaceuticals
– year: 2001
  ident: bb0005
  article-title: Bioanalytical Method Validation
– volume: 125
  start-page: 297
  year: 2016
  end-page: 305
  ident: bb0055
  article-title: Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs
  publication-title: Biochimie
– volume: 54
  start-page: 1427
  year: 2014
  end-page: 1457
  ident: bb0045
  article-title: Specificity of infant digestive conditions: some clues for developing relevant
  publication-title: Crit. Rev. Food Sci. Nutr.
– year: 2016
  ident: bb0125
  article-title: model simulating gastro-intestinal digestion in the pediatric population (neonates and young infants)
  publication-title: AAPS PharmSciTech
– ident: bb0145
  article-title: Products FAQ
– volume: 16
  start-page: 1344
  issue: 6
  year: 2014
  ident: 10.1016/j.ejps.2017.08.003_bb0160
  article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels
  publication-title: AAPS J.
  doi: 10.1208/s12248-014-9672-x
– year: 2007
  ident: 10.1016/j.ejps.2017.08.003_bb0085
– volume: 8
  start-page: 1293
  issue: 10
  year: 2012
  ident: 10.1016/j.ejps.2017.08.003_bb0140
  article-title: Ontogeny of oral drug absorption processes in children
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425255.2012.698261
– volume: 37
  start-page: 387
  year: 1962
  ident: 10.1016/j.ejps.2017.08.003_bb0135
  article-title: Some aspects of gastric function in the newborn
  publication-title: Arch. Dis. Child.
  doi: 10.1136/adc.37.194.387
– ident: 10.1016/j.ejps.2017.08.003_bb0100
– start-page: 773
  year: 2016
  ident: 10.1016/j.ejps.2017.08.003_bb0035
  article-title: et al.
– volume: 72
  start-page: 677
  issue: 5
  year: 1983
  ident: 10.1016/j.ejps.2017.08.003_bb0120
  article-title: Feeding the low-birth-weight infant. III. Diet influences bile acid metabolism
  publication-title: Pediatrics
  doi: 10.1542/peds.72.5.677
– year: 2001
  ident: 10.1016/j.ejps.2017.08.003_bb0005
– volume: 77
  start-page: 40
  year: 2015
  ident: 10.1016/j.ejps.2017.08.003_bb0115
  article-title: Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2015.05.023
– year: 2016
  ident: 10.1016/j.ejps.2017.08.003_bb0125
  article-title: In vitro model simulating gastro-intestinal digestion in the pediatric population (neonates and young infants)
  publication-title: AAPS PharmSciTech
– volume: 125
  start-page: 297
  year: 2016
  ident: 10.1016/j.ejps.2017.08.003_bb0055
  article-title: Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2015.11.016
– volume: 2
  start-page: 364
  issue: 4
  year: 2010
  ident: 10.1016/j.ejps.2017.08.003_bb0195
  article-title: Drug development for pediatric populations: regulatory aspects
  publication-title: Pharmaceutics.
  doi: 10.3390/pharmaceutics2040364
– year: 2005
  ident: 10.1016/j.ejps.2017.08.003_bb0180
– volume: 54
  start-page: 1427
  issue: 11
  year: 2014
  ident: 10.1016/j.ejps.2017.08.003_bb0045
  article-title: Specificity of infant digestive conditions: some clues for developing relevant in vitro models
  publication-title: Crit. Rev. Food Sci. Nutr.
  doi: 10.1080/10408398.2011.640757
– volume: 15
  issue: 8
  year: 2009
  ident: 10.1016/j.ejps.2017.08.003_bb0050
  article-title: Furosemide: a review of its use in infants and children
  publication-title: Pediatr. Pharmacol.
– volume: 7
  start-page: 3989
  issue: 9
  year: 2016
  ident: 10.1016/j.ejps.2017.08.003_bb0165
  article-title: Comparison of lipases for in vitro models of gastric digestion: lipolysis using two infant formulas as model substrates
  publication-title: Food Funct.
  doi: 10.1039/C6FO00158K
– ident: 10.1016/j.ejps.2017.08.003_bb0185
– volume: 443
  year: 2013
  ident: 10.1016/j.ejps.2017.08.003_bb0175
– start-page: 2016
  year: 2016
  ident: 10.1016/j.ejps.2017.08.003_bb0015
– year: 2006
  ident: 10.1016/j.ejps.2017.08.003_bb0080
  article-title: EC Regulation No 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 1768/92, directive 2001/20/EC, directive 2001/83/EC and regulation (EC) No 726/2004
  publication-title: Off. J. Eur. Union
– volume: 6
  start-page: 231
  issue: 3
  year: 2007
  ident: 10.1016/j.ejps.2017.08.003_bb0155
  article-title: Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd2197
– volume: 101
  start-page: 3360
  issue: 9
  year: 2012
  ident: 10.1016/j.ejps.2017.08.003_bb0190
  article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.23205
– volume: 99
  start-page: 2544
  issue: 6
  year: 2010
  ident: 10.1016/j.ejps.2017.08.003_bb0105
  article-title: Biowaiver monographs for immediate release solid oral dosage forms: furosemide
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.22030
– ident: 10.1016/j.ejps.2017.08.003_bb0090
– volume: 26
  start-page: 1901
  issue: 8
  year: 2009
  ident: 10.1016/j.ejps.2017.08.003_bb2015
  article-title: In vitro gastrointestinal lipolysis of four formulations of piroxicam ans cannarizine with the self emulsifying excipients Labrosol and Gelucire 44/14
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-009-9906-2
– volume: 4
  start-page: 793
  issue: 6
  year: 1959
  ident: 10.1016/j.ejps.2017.08.003_bb0070
  article-title: On the bile acids in duodenal contents of infants and children bile acids and steroids 72
  publication-title: Clin. Chim. Acta
  doi: 10.1016/0009-8981(59)90030-0
– year: 2014
  ident: 10.1016/j.ejps.2017.08.003_bb0010
– ident: 10.1016/j.ejps.2017.08.003_bb0095
– volume: 11
  year: 2015
  ident: 10.1016/j.ejps.2017.08.003_bb0130
  article-title: Diuretics for transient tachypnoea of the newborn
  publication-title: Cochrane Database Syst. Rev.
– volume: 29
  start-page: 725
  issue: 6
  year: 1986
  ident: 10.1016/j.ejps.2017.08.003_bb0030
  article-title: Reduced bioavailability and effect of furosemide given with food
  publication-title: Eur. J. Clin. Pharmacol.
  doi: 10.1007/BF00615967
– volume: 457
  start-page: 327
  issue: 1
  year: 2013
  ident: 10.1016/j.ejps.2017.08.003_bb0110
  article-title: In vitro gastrointestinal model (TIM) with predictive power, even for infants and children?
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2013.07.053
– volume: 105
  start-page: 876
  issue: 3
  year: 1993
  ident: 10.1016/j.ejps.2017.08.003_bb0060
  article-title: Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans
  publication-title: Gastroenterology
  doi: 10.1016/0016-5085(93)90908-U
– volume: 83
  start-page: 279
  year: 2013
  ident: 10.1016/j.ejps.2017.08.003_bb0170
  article-title: Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2013.05.011
– ident: 10.1016/j.ejps.2017.08.003_bb0145
– volume: 12
  start-page: 413
  issue: 3
  year: 1995
  ident: 10.1016/j.ejps.2017.08.003_bb0020
  article-title: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability
  publication-title: Pharm. Res.
  doi: 10.1023/A:1016212804288
– volume: 62
  start-page: 811
  issue: 5
  year: 1978
  ident: 10.1016/j.ejps.2017.08.003_bb0075
  article-title: The use of furosemide in the treatment of edema in infants and children
  publication-title: Pediatrics
  doi: 10.1542/peds.62.5.811
– volume: 67
  start-page: 651
  issue: 5
  year: 2015
  ident: 10.1016/j.ejps.2017.08.003_bb0150
  article-title: Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach
  publication-title: J. Pharm. Pharmacol.
  doi: 10.1111/jphp.12365
– volume: 15
  start-page: 11
  issue: 1
  year: 1998
  ident: 10.1016/j.ejps.2017.08.003_bb0065
  article-title: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms
  publication-title: Pharm. Res.
  doi: 10.1023/A:1011984216775
– volume: 71
  start-page: 207
  issue: 4
  year: 1997
  ident: 10.1016/j.ejps.2017.08.003_bb0040
  article-title: Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age
  publication-title: Biol. Neonate
  doi: 10.1159/000244419
– volume: 40
  start-page: 429
  issue: 3
  year: 1996
  ident: 10.1016/j.ejps.2017.08.003_bb0025
  article-title: Effect of human milk or formula on gastric function and fat digestion in the premature infant
  publication-title: Pediatr. Res.
  doi: 10.1203/00006450-199609000-00011
SSID ssj0006870
Score 2.3101165
Snippet The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 191
SubjectTerms Digestion
Diuretics - chemistry
Diuretics - metabolism
Drug solubilization
Fasting - metabolism
Food-Drug Interactions
Furosemide
Furosemide - chemistry
Furosemide - metabolism
Gastric Mucosa - metabolism
Humans
Hydrogen-Ion Concentration
In vitro models
Infant
Infant, Newborn
Intestine, Small - metabolism
Models, Biological
Neonates and young infants
Pediatric
Powders
Solubility
Stomach - chemistry
Tablets
Title Studying furosemide solubilization using an in vitro model simulating gastrointestinal digestion and drug solubilization in neonates and young infants
URI https://dx.doi.org/10.1016/j.ejps.2017.08.003
https://www.ncbi.nlm.nih.gov/pubmed/28803922
https://www.proquest.com/docview/1928782038
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELba7YUL4s3yqIyEeqFh48SOs8eqolpAVJVopd4sOx6vUtF0tdlF2gs_g9_LjJNsBYgeOMb2OJZnMp6JZ75h7G3qVGVh6hJIK5nIEGxSWouuiiB_wmY6yynf-ctpMbuQny7V5Q47HnJhKKyy1_2dTo_aum-Z9Ls5WdT15Gs6zcoUXWaBQkqwdbtsL8PTvhyxvaOPn2enW4VclLFmHI1PiKDPnenCvOBqQajdQkckz6F21t_n07_sz3gOnTxg93sDkh91a3zIdqB5xA7OOgTqzSE_v02oag_5AT-7xabePGY_KW6QMpt4IBxLuK49cBI_ipHtMjI5hcLPuW143fDv9Wp5w2O5HN7W17HWF3bObYvtBDWBGoKW4-M9FVHbxnO_XM__nBUna4B-1UMbx2xIzWBroECcJ-zi5MP58SzpSzMkVa6KVSKcAw0KVOkEeKuzwoWsqHKJbA9aCz-VQtoSeyzaPIBepPPKoXtZgEr9FPKnbNTcNPCc8WhROBIQKaUKqQMVgg4ePVenldVjJgaGmKrHLafyGd_MEKB2ZYiJhphoqKZmmo_Zuy3NokPtuHO0GvhsfpM9g8fKnXRvBqEw-FHSTYvFnVy3Bs3mkoAI83LMnnXSsl1HhhoTxTR78Z9vfcnu0RPlQwr1io1WyzW8RsNo5fbZ7vsfYr8X_18xhhJb
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa69LBdhr2bPTVg6GU14pcs51gUK9K1DQosBXoTJJsKXKxuECcD8kf2e0fKdoptWA-7SqIsiBRFWuRHgE-hlYXBsQ0wLNIgdc4EuTHkqkTsT5hYxQnnO59Ps8ll-vVKXu3AUZ8Lw2GVne5vdbrX1l3LqNvN0aKqRt_CcZyH5DJHJKQMW_cAdlMuaj2A3cOT08l0q5Cz3NeM4_EBE3S5M22YF14vGLU7Uh7Js6-d9ff99C_7099Dx0_gcWdAisN2jU9hB-tnsH_RIlBvDsTsLqGqORD74uIOm3rzHH5y3CBnNgnHOJZ4U5UoWPw4RrbNyBQcCj8XphZVLX5Uq-Wt8OVyRFPd-Fpf1Dk3DbUz1ARpCF5O6d-pmNrUpSiX6_mfs9JkNfKvemz8mA2rGWp1HIjzAi6Pv8yOJkFXmiEoEpmtgshaVChR5jbC0qg4sy7OiiQltjulonJMjDA59RiyeZC8SFtKS-5lhjIsx5i8hEF9W-MeCG9RWBaQNE2lCy1K55QryXO1Sho1hKhniC463HIun_Fd9wFq15qZqJmJmmtqhskQPm9pFi1qx72jZc9n_ZvsabpW7qX72AuFpkPJLy2GdnLdaDKbcwYiTPIhvGqlZbuOmDQmGaXx6__86gd4OJmdn-mzk-npG3jEPZwbGcm3MFgt1_iOjKSVfd8dgl-mEhRB
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Studying+furosemide+solubilization+using+an+in+vitro+model+simulating+gastrointestinal+digestion+and+drug+solubilization+in+neonates+and+young+infants&rft.jtitle=European+journal+of+pharmaceutical+sciences&rft.au=Klitgaard%2C+Mette&rft.au=Sassene%2C+Philip+Jonas&rft.au=Selen%2C+Arzu&rft.au=M%C3%BCllertz%2C+Anette&rft.date=2017-11-15&rft.eissn=1879-0720&rft.volume=109&rft.spage=191&rft_id=info:doi/10.1016%2Fj.ejps.2017.08.003&rft_id=info%3Apmid%2F28803922&rft.externalDocID=28803922
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0928-0987&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0928-0987&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0928-0987&client=summon